Sep. 23 at 9:06 PM
$NMRA H.C. Wainwright reiterated BUY rating /
$18.00 PT on NMRA in July 2025, following company's selection of a new lead M4 PAM candidate, NMRA-861, for schizophrenia treatment. Analyst Action:
Date: July 10, 2025
Analyst Firm: H.C. Wainwright
Rating: Buy
Price Target:
$18.00
Reasons for Reiterated Target:
New Lead Candidate: Neumora selected NMRA-861, a new M4 positive allosteric modulator (PAM), to advance into clinical trials.
Preclinical Safety: Unlike the previous candidate NMRA-266, NMRA-861 did not exhibit convulsions in preclinical animal studies.
Increased Potency: NMRA-861 is noted to be more potent than earlier candidate.
Strategic Approach: The company believes targeting allosteric site of M4 muscarinic receptors allows for greater selectivity and a more appropriate approach to neuropsychiatric disorders.
Recent:
Initiated Phase 1 Study: A Phase 1 study for NMRA-861 has begun in healthy adults and patients with stable schizophrenia, with data expected in the first quarter of 2026.
